Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Teleflex Q3 revenue slightly beats estimates

By Reuters News


Overview

  • US medical device maker's Q3 revenue up 0.2% yr/yr, slightly beating analyst expectations

  • Adjusted diluted EPS for Q3 rose to $2.63, beating consensus

  • Company repurchased $350 mln in stock since July 1, 2026


Outlook

  • Teleflex maintains 2026 pro forma adjusted constant currency revenue growth guidance at 3.5%-4.5%

  • Company raises 2026 adjusted diluted EPS guidance to $7.50-$7.75 from continuing operations

  • Teleflex lowers 2026 GAAP revenue growth guidance to 13.2%-14.2% due to foreign exchange changes


Result Drivers

  • SEGMENT PERFORMANCE - Vascular and Surgical units delivered mid-single-digit growth, while Interventional returned to modest growth, per CEO Jason Weidman

  • TARIFF REFUNDS - Q3 results benefited from $16.5 mln in IEEPA tariff refunds recognized in continuing operations

  • MARGIN EXPANSION - Co cited margin expansion as contributing to robust EPS growth, even when excluding tariff refunds, per CEO Jason Weidman


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Slight Beat*

$567.78 mln

$566.77 mln (11 Analysts)

Q3 Adjusted EPS

Beat

$2.63

$1.90 (12 Analysts)

Q3 EPS continuing operations

$1.30

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 8 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Teleflex Incorporated is $155.00, about 3.4% above its November 4 closing price of $149.87

  • The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 15 three months ago


Reuters Recommended Reads

  • Nov 4 - Insulet Q3 revenue beats estimates on strong Omnipod sales

  • Nov 3 - AtriCure Q3 revenue beats expectations on strong sales of pain management and appendage devices

  • Nov 4 - LivaNova Q3 revenue beats estimates on cardiopulmonary segment strength


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.